Biomarkers: An Important Tool for Diagnosing and Treating Breast Cancer

Simple item page
dc.contributor.authorSharma, Anilen_US
dc.contributor.authorChakraborty, Tulshien_US
dc.contributor.authorGupta, Sumeeten_US
dc.contributor.authorSharma, Abhisheken_US
dc.contributor.authorPahari, Pratyay Kumaren_US
dc.date.accessioned2020-11-18T10:30:14Z
dc.date.available2020-11-18T10:30:14Z
dc.date.issued2020-07
dc.description.abstractBreast cancer is a type of tumor in which individual cases deviate from each other in morphology, protein expression, molecular phenotype, genetic characteristics, and prognosis. Worldwide, breast cancer is the most-common invasive cancer in women. A patient with breast cancer may have the following symptoms:-lumps, skin dimples, nipple discharge, nipple height, nipple withdrawal, pain and burning sensation. There are many causes and risks of breast cancer, including family history (heriditary), obesity, active smoking, early and late childbearing, breastfeeding for less than two weeks, exposure to estrogen and oral contraceptive pills. Most breast cancers are diagnosed through estrogen receptor (ER) -positive determination and rely on estrogen for cell growth and survival. Breast cancer treatment has encountered a few progressions in the previous decades with the revelation of explicit prescient prognostic biomarkers that make conceivable the use of individualized treatments.Blocking estrogen biosynthesis by aromatase inhibitors (AI) has, subsequently, become a first-line endocrine treatment for menopausal ladies with ER-positive breast disease. Various conventional diagnosing and treating methods of breast cancer is available but there have limitation of accuracy and treating. For that reason now a day’s various biomarkers like Molecule or Biochemical biomarkers like Estrogen receptor, Progesterone receptor, human epidermal growth factor receptor 2 (HER2), human Mammaglobin(H-MAM), Osteopontin, Fibroblast Growth Factor Receptor 2 (FGFR2), Phosphatase and tensin homolog (PTEN), Physiologic Biomarkers like Carcinoma Antigen 15-3(CA 15–3), Cancer Antigen 125 (CA 125), Prostate specific antigen (PSA) and Anatomic Biomarkers Oncotype Dx, and Cystic fibrosis Trans-membrane conductance regulator(CFTR). These biomarkers are of great importance in the evaluation and diagnosis process, which leads to better patient’s care and protection of the patients. Due to its various advantages, biomarkers are considered as an innovative tool in the progression of breast cancer diagnosis and treatment.en_US
dc.identifier.affiliationsM.M.College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Haryana, Indiaen_US
dc.identifier.citationSharma Anil, Chakraborty Tulshi, Gupta Sumeet, Sharma Abhishek, Pahari Pratyay Kumar. Biomarkers: An Important Tool for Diagnosing and Treating Breast Cancer. Journal of Pharmaceutical Research International. 2020 Jul; 32(12): 46-54en_US
dc.identifier.issn2456-9119
dc.identifier.issn2231-2919
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/215818
dc.languageenen_US
dc.publisherSCIENCEDOMAIN internationalen_US
dc.relation.issuenumber12en_US
dc.relation.volume32en_US
dc.source.urihttps://doi.org/10.9734/JPRI/2020/v32i1230559en_US
dc.subjectBreast canceren_US
dc.subjectbreast tumoren_US
dc.subjectbiomarkersen_US
dc.subjectBRCA1en_US
dc.subjectBRCA2en_US
dc.titleBiomarkers: An Important Tool for Diagnosing and Treating Breast Canceren_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
jpri2020v32n12p46.pdf
Size:
202.06 KB
Format:
Adobe Portable Document Format
Download
Collections
Journal of Pharmaceutical Research International